Ultragenyx Pharmaceutical | RARE - Interest Expense On Debt


Ultragenyx Pharmaceutical reported $22M in Interest Expense on Debt for its fiscal quarter ending in June of 2026.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Agios Pharmaceuticals USD 1.11B 76.57M Jun/2026
Alnylam Pharmaceuticals USD 82.05M 12.76M Jun/2026
BioCryst Pharmaceuticals USD 21.71M 7.58M Jun/2026
BioMarin Pharmaceutical USD 63.29M 48.34M Jun/2026
Immunic 197K 222K Dec/2025
Insmed USD 18.84M 1.24M Jun/2026
Ionis Pharmaceuticals USD 18M 1000K Jun/2026
Karyopharm Therapeutics USD 12.55M 66K Mar/2026
Kyowa Hakko Kirin JPY 2.27B 1.84B Mar/2026
MacroGenics USD 4.89M 1.55M Mar/2026
Moderna USD 10.96B 527M Jun/2026
Neurocrine Biosciences USD 1.1M 0 Mar/2024
PTC Therapeutics USD 3.25B 381.37M Jun/2026
Puma Biotechnology USD 3.37M 11K Jun/2024
Regeneron Pharmaceuticals USD 11M 1.9M Jun/2026
Sarepta Therapeutics USD 21.51M 205K Jun/2026
Ultragenyx Pharmaceutical USD 22M 1000K Jun/2026
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025